Opthea Limited unveils strategy to target rare lung disease LAM with OPT-302 relaunch
I'm PortAI, I can summarize articles.
Opthea Limited has relaunched its operations to focus on developing OPT-302 for treating Lymphangioleiomyomatosis (LAM), a rare lung disease. The company boasts a strong intellectual property portfolio with protection until 2046 and a comprehensive clinical and manufacturing data package. Led by Executive Chairman Dr. Jeremy Levin, Opthea reports a pro-forma cash balance of A$37.6 million, supported by an R&D tax incentive, and has reinstated its ASX quotation.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments